Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor (IC50 = 0.02 nM) that can across the blood-brain barrier (BBB). Monoamine Oxidase B inhibitor 1 shows antioxidant and anti-neuroinflammatory activities that can be used in the study of Parkinson’s disease[1].

In cellular experiments, Monoamine Oxidase B inhibitor 1 (compound 14a; 0.5-10.0 μM) could significantly decrease the production of NO and TNF-α in LPS-stimulated BV-2 cells [1].

In in vivo acute and subacute MPTP-induced mice model of Parkinson’s disease, Monoamine Oxidase B inhibitor 1 (compound 14a; 6-37.4 mg/kg; oral administration) could significantly improve most behavioral disorders, restore the dopamine content and decrease the MDA content in the mice striatum [1].